Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure

September 22,2024

Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.

Significant Phase 2 Findings Support Zilebesiran as Anti-Hypertension Treatment

zilebesiran injection phase 2 results : r/hypertension

Professor Bryan Williams MD FMedSci on LinkedIn: Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in…

New Results from KARDIA-1 Phase 2 Study of Zilebesiran Presented at the American Heart Association (AHA) Scientific Sessions 2023 - Alnylam

alny-20211231

Future treatments in hypertension: Can we meet the unmet needs of patients? - ScienceDirect

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor‐Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen–Targeting Small Interfering RNA

Innovative Treatment for Hypertension: One Shot Every Quarter or Even Six Months • BioPharma Media

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran - European Pharmaceutical Manufacturer